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Stage III colon cancer
Adjuvant 5-ﬂuorouracil
Varying treatment efﬁcacyWe investigated the hypothesis that the varying treatment efﬁcacy of adjuvant 5-ﬂuorouracil (5FU) in stage III
colon cancer is linked to the TP53mutational status.
ABCSG-90 was a prospective randomized trial in which effect of adjuvant 5FU was studied in stage III colon can-
cer patients. Tumor material of 70% of these patients (389/572) was available for analysis of the biomarker TP53
using a TP53-gene-speciﬁc Sanger sequencing protocol.
Median follow-upwas 88months. TP53mutation frequencywas 33%. A signiﬁcant interaction between TP53 sta-
tus, outcomes and nodal category was found (P= 0.0095). In the N1 category, TP53wildtype patients had signif-
icantly better overall survival than TP53mutated (81.0% vs. 62.0% overall survival at 5 years; HR= 2.131; 95% CI:
1.344–3.378; P = 0.0010). In the N2 category, the TP53 status did not affect survival (P = 0.4992). In TP53
wildtype patients, the prognostic signiﬁcance ofN categorywas signiﬁcantly enhanced (P=0.0002). In TP53mu-
tated patients, survival curves of N1 and N2 patients overlapped and nodal category was no longer prognostic.
The biomarker TP53 independently predicted effect of adjuvant 5FU in N1 colon cancer patients. TP53 was not
predictive in N2 patients, in whom 5FU is known to have no effect.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Adjuvant chemotherapy is recommended for all patients with lymph-
node positive colon cancer (Gill et al., 2004; Greene et al., 2002a). For de-
cades, 5-ﬂuorouracil (5FU) was the only drug demonstrating meaningful
activity in colorectal cancer and is still used in any modern adjuvant che-
motherapy regimens for colon cancer (Chau and Cunningham, 2006). AtBreast and Colorectal Cancer
alin-ﬁxed parafﬁn-embedded;
Medical University of Vienna,
D. Kandioler).
. This is an open access article underthe beginning of this century, oxaliplatin, irinotecan, capecitabine,
cetuximab, and bevacizumab became available. But the major, dramatic
progress promised by newbiological and targeted agents failed to emerge
(Brenner et al., 2014; Cassidy et al., 2008; Saltz et al., 2008; Tol et al., 2009;
Hecht et al., 2009). Still no drug shows greater single agent activity than
5FU. But it is general knowledge that treatment efﬁcacy varies substan-
tially among 5FU-treated patients of similar stage and baseline risk fac-
tors. The question why remained unanswered although it is burning
since the early days of 5FU.
5FU induces DNA-damage in rapidly growing cells. It is generally
accepted that wild type TP53 is responsible for apoptosis induction in
response to DNA-damage. In more than 30% of colon cancers TP53 is
mutated and apoptosis cannot be induced. However, clinical reports
about the role of the TP53 status for response to adjuvant chemotherapythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Petersen et al., 2001; Ahmed et al., 2008; Bleeker et al., 2001).
The aimof this studywas to evaluatewhether andhow the TP53mu-
tational status is linked to the varying efﬁcacy of 5FU treatment in stage
III colon cancer. For this purpose, we performed a retrospective bio-
marker analysis in a prospective randomized cohort of stage III colon
cancer patients treated with adjuvant 5FU. The prospective randomized
trial (ABCSG-90) was initially reported by the Austrian Breast and Colo-
rectal Cancer Study Group (ABCSG) in 2005 (Schippinger et al., 2005).
2. Materials and Methods
2.1. Patient Cohort
Between 1991 and 1999, 572 stage III colon cancer patients were
recruited for ABCSG-90 in order to investigate the inﬂuence of adding
levamisole (LEV) and/or interferon (INF) alpha to adjuvant ﬂuorouracil.
In 2005 the results of ABCSG-90 were published. It was reported that
neither LEV nor INF improved the efﬁcacy of adjuvant 5FU in stage III
colon cancer (Schippinger et al., 2005). Patient inclusion criteria were
histologically proven lymph node positive carcinoma of the colon
(stage III), age between 18 and 80 and curative resection. Rectal cancers
were excluded.
2.2. Tumor Material
Formalin-ﬁxed parafﬁn-embedded (FFPE) tissue samples of the sur-
gical specimens from 389 patients were available for the retrospective
TP53 biomarker analysis, corresponding to 70% of the original 572
study patients. The 389 analyzed patients were equally distributed be-
tween the randomized treatment arms of ABCSG-90.
2.3. Ethics
The retrospective biomarker analysis was approved by the local
ethics committee of the Medical University of Vienna (EK 761/2008).
2.4. TP53 Sequencing
Themutational status of TP53was assessed using DNA extracts from
archived FFPE material from the surgical specimens. TP53-gene-speciﬁc
Sanger sequencing was used for gene analysis. (MARK53gssx6, p53-
gene-speciﬁc sequencing kit; Mark53 Ltd.; www.mark53.com; Vienna).
Genetic variations in the TP53 gene were reported and interpreted ac-
cording to recommendations of the Human Genome Variation Society
(www.hgvs.org) (den Dunnen and Antonarakis, 2000).
The reference genomic sequence used for TP53 was NM_000546.5
and U94788 (NCBI GenBank).
The functional activity of TP53 mutations was classiﬁed based on
the overall transcriptional activity on eight different promoters as mea-
sured in yeast assays by Kato et al. (Kato et al., 2003; Petitjean et al.,
2007) : TP53mutants considered to have amedian transcriptional activ-
ity N75% were classiﬁed as wildtype for the calculation. A median tran-
scriptional activity of b75%was considered partially functional and was
classiﬁed as mutant for calculation.
2.5. Statistical Methods
Continuous data are described bymedian,minimum, andmaximum.
Categorical data are described with absolute and relative frequencies. A
chi-square test was used to assess for group differences for binary and
nominal variables. For ordinal variables, a trend chi-square test was
used. In the case of sparse data, Fisher's Exact test or exact chi-square
tests were used.
The primary outcomemeasure was overall survival. Overall survival
is deﬁned as the time between the date of randomization until deathfrom any cause or censored at last time known to be alive. Median
follow-up time was calculated using the Kaplan–Meier method, in
which deaths are censored for further follow-up. Survival probabilities
were estimated by Kaplan–Meier graphs, and group differences were
assessed by log-rank test. A Cox regression model was used to assess
group differences by hazard ratios (HR) and corresponding 95% conﬁ-
dence intervals (CI). A Cox regressionmodel was used to assess interac-
tions between prognostic factors and TP53mutation status. In the case
of a signiﬁcant interaction, separate subgroup analyseswere performed.
Multiple Cox regressionmodels were ﬁtted to assess the impact of TP53
on survival above that of standard prognostic factors.
Statistical calculations were performed with SAS® (SAS Institute
Inc., Cary, NC, USA). All p-values are two-sided, and P ≤ 0.05was consid-
ered statistically signiﬁcant.
Colon cancers were classiﬁed according to the UICC/AJCC staging
system (N1 = metastasis in one to three regional lymph nodes; N2 =
metastasis to four or more regional lymph nodes) (Greene et al.,
2002b). No rectal cancers were included.
3. Results
TP53 sequencing analysiswas successful in all 389 specimens. TP53mu-
tationswere detected in 129 patients (33%).Mutations are characterized in
Table 1. Three mutants had a median transcriptional activity N75% and
were classiﬁed as wildtype for the calculation. Six mutants were only par-
tially functional and were classiﬁed as mutant for calculation. Four muta-
tions, though located in the introns, had a predicted effect on splicing and
were classiﬁed as mutant (NNsplice 0.9, HSF_V2.3) (Petitjean et al., 2007).
Four silent mutations had a predicted effect on splicing andwere classiﬁed
as mutant. Seven patients had two mutations in the TP53 gene.
The prognostic covariates are shown in Table 2. The frequency of TP53
mutations did not differ between nodal status (N1, N2; P=0.187), tumor
stages (IIIA, IIIB, IIIC; P = 0.445), or between the treatment arms of the
ABCSG-90 (ﬂuorouracil, ﬂuorouracil + LEV, ﬂuorouracil + INF,
ﬂuorouracil + LEV + INF; P = 0.148).
Median age was 63.3 years (min 20.2 and max 79.2 years). Median
follow-up timewas 88 months. The ﬁve-year overall survival of the an-
alyzed 389 patients was 71.2%, which is comparable to ﬁve-year overall
survival reported for the original cohort of the ABCSG-90, which includ-
ed 572 patients.
3.1. Nodal Category Speciﬁc Interaction Between TP53 Status and Survival
Overall, TP53wildtype patients performed better than TP53mutant
patients, but this difference was not signiﬁcant (P = 0.0640). A signiﬁ-
cant interaction between TP53 status and lymph node categories was
seen in Cox regression models (P = 0.0095) and justiﬁed the examina-
tion of the effect of TP53 status in the nodal categories N1 versus N2
separately.
In N1 patients, the ﬁve-year overall survival was 81.0% for TP53
wildtype patients compared to 62.0% in TP53 mutant patients (HR =
2.131 (95 % CI: 1.344–3.378); P = 0.0010) (Fig. 1A). In N2 patients, the
TP53 status did not affect the overall survival (P = 0.4992). The ﬁve-
year overall survival was 66.3% for TP53 wildtype patients and 69.3%
for mutant patients (HR = 0.834 (95% CI: 0.493–1.412)) (Fig. 1B).
After adjustment for other prognostic factors, including sex, age as
continuous variable, grading, therapy, and tumor location, the TP53
mutational status remained a signiﬁcant factor for overall survival in
N1 patients (HR = 1.886 (95% CI: 1.172–3.036) P = 0.0090). In N2 pa-
tients, TP53 remained a non-signiﬁcant factor for overall survival.
As expected, N1 patients had a signiﬁcant better survival than N2
patients (P = 0.0117) (Fig. 2). In TP53 wildtype patients, discrimination
between favorable and poor survival prognosis by nodal category was
improved (P = 0.0002) (Fig. 3A). In TP53 mutant patients, survival
curves of N1 and N2 patients overlapped (P = 0.6393) and nodal cate-
gory was no longer prognostic in TP53mutant patients (Fig. 3B).
Table 1
TP53mutations.
Type of TP53mutationa Nr. of patients with
that mutation
Exon
c.102dupC p.(Pro36fs) 1 4
c.216dupC p.(Val73fs) 1 4
c.326TNC p.(Phe109Ser) 1 4
c.332TNG p.(Leu111Arg) 1 4
c.338TNG p.(Phe113Cys) 1 4
c.341TNA p.(Leu114Ter) 1 4
c.375GNA p.? 1 4
c.380CNT p.(Ser127Phe) 1 5
c.402TNA p.(Phe134Leu) 1 5
c.404GNT p.(Cys135Phe) 1 5
c.405CNG p.(Cys135Trp) 1 5
c.406CNT p.(Gln136Ter) 1 5
c.413CNT p.(Ala138Val) 1 5
c.452CNA p.(Pro151His) 1 5
c.454_466del p.(Pro152fs) 1 5
c.455CNT p.(Pro152Leu) 1 5
c.470TNG p.(Val157Gly) 1 5
c.475GNC p.(Ala159Pro) 1 5
c.485TNG p.(Ile162Ser) 1 5
c.493CNT p.(Gln165Ter) 1 5
c.514_524del p.(Val172fs) 1 5
c.517GNA p.(Val173Met) 1 5
c.524GNA p.(Arg175His) 10 5
c.527GNT p.(Cys176Phe) 1 5
c.536ANC p.(His179Pro) 1 5
c.553delA p.(Ser185fs) 1 5
c.559 + 1GNT p.? 1 Intron 5
c.571_573delCCT p.(Pro191del) 1 6
c.576_577delinsCA p.[(Gln192His(;)His193Asn)] 1 6
c.578ANG p.(His193Arg) 1 6
c.578ANT p.(His193Leu) 1 6
c.580CNT p.(Leu194Phe) 1 6
c.583ANT p.(Ile195Phe) 1 6
c.586CNT p.(Arg196Ter) 1 6
c.612_613insA p.(Tyr205fs) 1 6
c.626_627delGA p.(Arg209fs) 1 6
c.637CNT p.(Arg213Ter) 9 6
c.638GNA p.(Arg213Gln) 1 6
c.641ANG p.(His214Arg) 1 6
c.646GNA p.(Val216Met) 1 6
c.650_658del p.(Val217_Tyr220delinsAsp) 1 6
c.672 + 1GNC p.? 1 Intron 6
c.672 + 1GNT p.? 1 Intron 6
c.700TNG p.(Tyr234Asp) 1 7
c.701ANG p.(Tyr234Cys) 1 7
c.706TNG p.(Tyr236Asp) 1 7
c.707ANC p.(Tyr236Ser) 1 7
c.711GNT p.(Met237Ile) 1 7
c.712TNC p.(Cys238Arg) 1 7
c.713GNA p.(Cys238Tyr) 1 7
c.716ANG p.(Asn239Ser) 1 7
c.723delC p.(Cys242fs) 1 7
c.726CNT p.? 2 7
c.733GNA p.(Gly245Ser) 2 7
c.737TNC p.(Met246Thr) 1 7
c.742CNT p.(Arg248Trp) 3 7
c.743GNA p.(Arg248Gln) 5 7
c.746GNT p.(Arg249Met) 2 7
c.747GNT p.(Arg249Ser) 1 7
c.750delC p.(251Ilefs) 1 7
c.770TNC p.(Leu257Pro) 1 7
c.772GNA p.(Glu258Lys) 1 7
c.773ANG p.(Glu258Gly) 1 7
c.782_782 + 1delGG p.? 1 7
c.794TNC p.(Leu265Pro) 1 8
c.799CNA p.? 1 8
c.800GNA p.(Arg267Gln) 2 8
c.809TNC p.(Phe270Ser) 1 8
c.811GNA p.(Glu271Lys) 1 8
c.814GNA p.(Val272Met) 3 8
c.814GNC p.(Val272Leu) 1 8
c.817CNT p.(Arg273Cys) 3 8
c.818GNA p.(Arg273His) 7 8
c.824GNA p.(Cys275Tyr) 1 8
Table 1 (continued)
Type of TP53mutationa Nr. of patients with
that mutation
Exon
c.832CNT p.(Pro278Ser) 1 8
c.833CNT p.(Pro278Leu) 1 8
c.844CNT p.(Arg282Trp) 3 8
c.851_852delCA p.(Thr284fs) 1 8
c.856GNA p.(Glu286Lys) 1 8
c.880delG p.(Glu294fs) 1 8
c.892GNT p.(Glu298Ter) 1 8
c.916CNT p.(Arg306Ter) 6 8
c.920-2ANG p.? 1 Intron 8
c.920-7_923delTTCCTAGCACT p.? 1 9/Intron 8
c.1009CNT p.(Arg337Cys) 1 10
c.1024CNT p.(Arg342Ter) 1 10
c.1025_1041dup17 p.(Leu348fs) 1 10
c.1027GNA p.(Glu343Lys) 1 10
c.1045GNT p.(Glu349Ter) 1 10
c.274CNT p.(Pro92Ser)b 1 4
c.548CNT p.(Ser183Leu)b 1 5
c.629ANG p.(Asn210Ser)b 1 6
c.277CNT p.(=)c 1 4
c.291CNT p.(=)c 1 4
c.525CNA p.(=)c 1 5
c.624CNT p.(=)c 1 6
c.699CNT p.(=)c 1 7
c.717CNT p.(=)c 1 7
c.1014CNT p.(=)c 1 10
c.1023CNT p.(=)c 1 10
c.1098CNT p.(=)c 1 10
a Mutations are reported according to Recommendations of the Human Genome Vari-
ation Society (www.hgvs.org).
b Mutations were considered and calculated as wildtype due to transactivation activity
N75%.
c Mutations were considered and calculated as wildtype as they were characterized as
silent mutations without affecting transcription, splicing or translation.
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The Cox regression models consistently showed a signiﬁcant inter-
action between TP53 status and traditional tumor stage (P = 0.0374).
Due to this signiﬁcant interaction, the effect of TP53 status was also in-










Stage IIIA 32 23 (71.9%) 9 (28.1%) 0.445
Stage IIIB 191 120 (62.8%) 71 (37.2%)
Stage IIIC 166 117 (70.5%) 49 (29.5%)
N1 (1-3) 223 143 (64.1%) 80 (35.9%) 0.1878
N2 (≥4) 166 117 (70.5%) 49 (29.5%)
Female 190 132 (69.5%) 58 (30.5%) 0.2806
Male 199 128 (64.3%) 71 (35.7%)
age 63.3 62.1 (20.2–79.1) 65.1 (32.8–79.2) 0.0062
Tumor grade
G1-G2 262 169 (64.5%) 93 (35.5%) 0.1751
G3 126 90 (71.4%) 36 (28.6%)
Location
Proximal 190 135 (71.1%) 55 (28.9%) 0.0845
Distal 199 125 (62.8%) 74 (37.2%)
Treatment arms
5FU 94 57 (60.6%) 37 (39.4%) 0.1482
5FU/interferon 102 76 (74.5%) 26 (25.5%)
5FU/levamisol 91 63 (69.2%) 28 (30.8%)
5FU/interferon/levamisol 102 64 (62.7%) 38 (37.3%)
Age is given as median (minimum–maximum), other categorical variables are described
with absolute frequencies and percentages.
Fig. 2. Kaplan–Maier estimates of cumultative survival of N1 patients versus N2 patients.
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was 91.3% versus 77.8% for TP53 mutant stage IIIA patients. The
HR was 3.008 (95% CI: 0.598–15.128; P = 0.1609). Statistical signiﬁ-
cance was not reached due to the small number of stage IIIA patients
(n = 32) and the small number of events (n = 6) in this subgroup.
In stage IIIB, the ﬁve-year survival for TP53 wildtype patients
was 79.0% versus 60.1% for TP53 mutant patients (HR = 2.014 (95%
CI: 1.246–3.258); P = 0.0036).
Stage IIICwas identical to N2, with no differential beneﬁt in relation
to TP53 status.
Factors evaluated in a multiple Cox regression model included sex,
age, grading, therapy, and tumor location. After adjustment for the
prognostic factors, the effect of TP53 on survival increased for stage
IIIA patients (HR = 8.775 (95% CI: 0.608–126.619); P = 0.1108),
although this was still non-signiﬁcant due to the small numbers of
patients and events as mentioned above. For stage IIIB patients,
the effect of TP53 on survival remained signiﬁcant (HR = 1.731 (95%
CI: 1.048–2.859); P = 0.0321). For stage IIIC patients, TP53 still had no
effect on survival (HR = 1.023 (95% CI: 0.584–1.791); P = 0.9379).
4. Discussion
Here we report the presence of a signiﬁcant interaction between
TP53 status and survival in stage III colon cancer patients treated with
adjuvant 5FU.We found that adjuvant 5FU resulted in amarked survival
beneﬁt in TP53 wildtype N1 patients, while N1 patients with mutant
TP53 performed as bad as N2 patients. The TP53 status independently
predicted the effect of adjuvant 5FU on survival in N1 patients while
there was no prediction of 5FU effect in N2 patients.
Colon cancer patients analyzed in this study were treated in the
1990s, when adjuvant 5FU was the standard of care in stage III colon
cancer. In the meantime it was recognized that adjuvant 5FU alone is
too week as chemotherapy at least for patients with advanced stage of
disease (N2 disease). Our results reﬂect this clinical experience on amo-
lecular level: TP53 predicted the effect of 5FU inN1patients but not inN2
patients, in whomwe do not await a therapeutic effect from 5FU alone.
It makes sense that in the absence of a therapeutic effect, a predictive
marker does not predict an effect.
Moreover, the here reported results support the hypothesis that
TP53 is not a prognostic but purely predictive type of biomarker (Pilat
et al., 2015). A purely predictive marker is considered to affect survival
only in the presence of a treatment. In the absence of a treatment or a
treatment effect, a pure predictivemarkerwill not interferewith surviv-
al (Pilat et al., 2015; Akiyama et al., 2014). In N2 patients TP53was not
predictive for an effect of 5FU most likely because there is no effect of
5FU in these advanced patients.
TP53 has been intensively studied in colorectal cancer. Some cur-
rently unexplained ﬁndings of meta-analyses appear in a new lightFig. 1. (A,B): Kaplan–Maier estimates of cumultative survivbased upon our ﬁndings. For instance, it has been reported that alter-
ations in the TP53 gene have little or no inﬂuence on survival in patients
treated with surgery alone, but were associated with worse survival for
patients treated with chemotherapy (Iacopetta, 2003). This again
supports our observation that TP53 is not a prognostic but a predictive
biomarker, inﬂuencing survival only in the presence of effective chemo-
therapy, as mentioned above. Another meta-analysis including more
than 18,000 patientswas published 2005, when 5FUwas standard adju-
vant chemotherapy (Munro et al., 2005). The analysis found “the ad-
verse impact of abnormal TP53 to be greater in colon cancer patients
with a lower baseline risk of dying”. This is consistent with our ﬁnding
that TP53was predictive for the effect of 5FU in N1 patients but not in
N2 patients.
The traditional T and N classiﬁcation, originally developed in the
1950s, still provides the most important prognostic information in
colon cancer and is guiding treatment decisions (Brenner et al., 2014;
Denoix and Schwartz, 1959). But in stage III colon cancer, prognostic in-
consistency is a well-known phenomenon. By contrast to stage II, stage
III patients usually are treated with adjuvant chemotherapy. Our IIIA/B
patients with wildtype TP53 status experienced a marked beneﬁt from
adjuvant 5FU, resulting in survival rates, which are comparable to
those of stage II colon cancer patients (Greene et al., 2002b;
Gunderson et al., 2010). A positive treatment effect occurred in TP53
wild type patients with stage IIIA/B but not IIIC as well as in wild type
N1 but not in N2 patients. Therefore the prognostic signiﬁcance of the
N category shown in Fig. 2 appeared to be enhanced in TP53wild type
patients as demonstrated in Fig. 3A. Our TP53 mutated stage IIIA/B or
N1 patients however, did as bad as our stage IIIC or N2 patients. Thus
a negative treatment effect occurred in TP53 mutated N1 patients but
not in N2 patients. Therefore N category was no longer prognostic inal by TP53 status (A) in N1 patients (B) in N2 patients.
Fig. 3. (A,B): Kaplan–Maier estimates of cumultative survival by lymphnode category (A) in TP53 wildtype patients (B) in TP53mutant patients.
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suggest that the TP53 marker status is linked to varying treatment
effects, which are likely to cause prognostic inconsistency in low risk
stage III colon cancer.
Biomarker research is complex in that proof of the clinical utility of a
biomarker is crucially linked to the analytical validity of the respective
biomarker-test. TP53 has not yet been recommended for clinical use as
a marker. Thus demonstration of the validity of TP53 tests was not top
of the list (Petersen et al., 2001; Munro et al., 2005; Roth et al., 2012).
Even though immunohistochemistry has been recognized as an insufﬁ-
cient method for indicating the presence of TP53 mutations, and even
though sequencing has been generally accepted as the ‘gold standard’
for investigating the TP53 status, methodology is still far from being
standardized. Various sequencing technologies and protocols are in
useworldwide, and there is evidence for dramatic variations in the sen-
sitivity and speciﬁcity of these methods (Petitjean et al., 2007; Edlund
et al., 2012; Soussi et al., 2006).
In recent years, we have identiﬁed numerous pitfalls while sequenc-
ing the TP53 gene.We believe that they arise from the special character-
istics of the TP53 gene itself and its mutations, as well as from technical
conditions such as FFPEmaterial, low copy numbers of tumor DNA in bi-
opsymaterial, or from the presence of normal cells in tumormaterial, to
list only a few. Over the years, we developed a p53-gene-speciﬁc se-
quencing protocol to addressing these and other conditions in a step-
wise fashion. We believe that this was a crucial step that allowed us to
uncover the here reported interaction between TP53 and chemotherapy
effect. Meanwhile, we proceeded to validating this standardized, TP53
gene-speciﬁc sequencing protocol in prospective biomarker trials
(www.ClinicalTrials.gov; PANCHONCT00525200, PARTNCT02140723).
ABCSG-90was a prospective randomized adjuvant colon cancer trial
investigating the inﬂuence of adding levamisole (LEV) and/or interferon
(INF) alpha to adjuvant ﬂuorouracil. Tumor material from only 70% of
patients from the ABCSG-90 was available for TP53 analysis in the
here reported study. Thus study limitations may arise from incomplete
analysis of the ABCSG-90 cohort as well as from the treatment combina-
tions, which were investigated in ABCSG-90. However, we believe that
random patient selection as well as different treatment effects is unlikely
to bias our results: The ABCSG-90 reported no difference in survival
among the investigated treatment arms. The patients included in the ret-
rospective biomarker analysis were distributed equally among treatment
armsasdemonstrated in Table 2. The TP53mutationswere also distributed
equally among treatment arms as well as among tumor stages and lymph
node categories. Andﬁnally theﬁve-year overall survival of ABCSG-90was
comparable to the smaller cohort analyzed for the biomarker.
In conclusion, TP53 was found to be a strong, independent marker
for predicting the effect of adjuvant 5FU chemotherapy in lymph node
positive colon cancer patients.We found that adjuvant 5FU resulted in a marked survival beneﬁt in
TP53 wildtype N1 patients, while TP53mutated N1 patients performed
as bad as N2 patients. The TP53 status independently predicted the
effect of adjuvant 5FU on survival in N1 patients while there was no
prediction of 5FU effect in N2 patients. The signiﬁcant interaction
between TP53 status, nodal category and treatment effect offers an
explanation for the known prognostic inconsistency in stage III
colon cancer patients. Further studies are needed to validate these
ﬁndings.Funding
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